Phase 3 Readout~month

Phase 3 Topline: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugen

Name: Phase 3 Topline: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugen
Start: 2029-12-01

December 1, 2029

Company: BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Indication: Brain Stem Glioma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugen — BZYR Phase 3 Readout | BioSniper